<DOC>
	<DOCNO>NCT02533700</DOCNO>
	<brief_summary>Peripheral T-cell Lymphoma ( PTCL ) heterogenic malignancy poor outcome . Five-year PFS OS patient receive classic CHOP regimen ( cyclophosphamide , vincristin , doxorubicin prednisone ) less 30 % .High dose intensive chemotherapy n't demonstrate good response . At present , standardized treatment protocol kind lymphoma . So , clinical trial encourage NCCN patient .</brief_summary>
	<brief_title>CEOP/IVE/GDP Compared With CEOP First-line Therapy Newly Diagnosed Adult Patients With PTCL</brief_title>
	<detailed_description>For less efficacy CHOP CHOP-like regimen , multi-drug combination strategy therapy tendency PTCL . The novel regimen IVE/MTX ( ifosfamide , vincristine , etoposide/methotrexate ) -ASCT ( autologous stem-cell transplantation ) pilot patient eligible intensive treatment , follow auto-stem cell transplantation . Five-years PFS ( progression-free survival ) OS ( overall survival ) 52 % 60 % respectively , significantly improve compare historical group treat anthracycline-based chemotherapy . The encouraged result extend peripheral T cell lymphoma-non specify ( PTCL-nos ) . Former study report GDP ( gemcitabine , cis-platinum , dexamethasone ) compare CHOP therapy strategy PTCL-NOS ( otherwise specify ) . The response rate 78.57 % GDP group 60.00 % CHOP group respectively . DFS ( disease-free survival ) 9.79 4.2 month two group . They conclude GDP superior CHOP . The main side-effect two regimen hematological toxicity . Furthermore , high-dose combine ASCT first-line therapy PTCL . However , 30 % patient PTCL chance receive ASCT multiple reason . So urgent explore new combination-therapy regimen improve outcome patient PTCL . The aim study compare response survival rate CEOP/IVE/GDP ( cyclophosphamide , vincristin , pharmorubicin prednisone/ ifosfamide , pharmorubicin , etoposide/ gemcitabine , cis-platinum , dexamethasone ) CEOP regimen , look forward superiority efficacy safety newly diagnose adult patient PTCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
	<mesh_term>Panniculitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Peripheral T Cell Lymphoma , Not Otherwise Specified , Angioimmunoblastic T Cell Lymphoma , ALKnegative Anaplastic Large Cell Lymphoma , Enteropathy Associated T Cell Lymphoma , Subcutaneous Panniculitis Like T Cell Lymphoma , acute Tcell leukemia/lymphoma SGOT ( serum glutamate oxaloacetate transaminase ) /SGPT ( serum glutamate pyruvate transaminase ) 2 time UNL ( upper normal limit ) serum creatinine 1.5 time UNL sign informed consent woman pregnancy lactation allergic intervention drug unsuitable study due severe complication enrol study past 6 month NK ( natural killer ) /T lymphoma ALKpositive Anaplastic Large Cell Lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>